House Patent Reform Bill: Battle Looms Over Reexam, Prior User Rights Provisions
Executive Summary
The six-year battle over patent reform legislation is not yet over as the pharmaceutical and biotechnology industries and other leading stakeholders are unhappy with provisions in the House bill that differ from the recently passed Senate measure.
You may also be interested in...
BioMarin Clears Path For Pompe Treatment After Knocking Out Genzyme Patents
Genzyme’s Myozyme patents invalid for being obvious, Patent Trial and Appeal Board finds in inter partes review.
House Judiciary Panel Revises Patent Re-Exam Provisions In Reform Bill; Sends Bill To Full House
Inter partes exam change brings bill more in line with Senate measure; House committee also rejects amendment to eliminate supplemental review provisions.
Patent Bill Drama Moves To House As Senate Hands Brand Pharma Victory
With the Senate poised to approve its version of the patent reform bill, House Judiciary Committee Chairman Lamar Smith, R-Texas, will soon be in the driver's seat of a piece of legislation that could significantly alter the relationships pharmaceutical companies have with both their licensing partners and generic adversaries.